Stockscreener 앱 받기
205.07
3.51%
6.96
시장 영업 전:
205.01
-0.06
-0.03%
전일 마감가:
$198.11
열려 있는:
$198.71
하루 거래량:
938.26K
Relative Volume:
0.70
시가총액:
$16.93B
수익:
$8.31B
순이익/손실:
$747.89M
주가수익비율:
22.86
EPS:
8.97
순현금흐름:
$1.23B
1주 성능:
+2.41%
1개월 성능:
-1.18%
6개월 성능:
-37.80%
1년 성능:
-21.00%
1일 변동 폭
$197.83
$205.31
1주일 범위
$196.50
$205.31
52주 변동 폭
$183.38
$347.72
Icon Plc Stock (ICLR) Company Profile
ICLR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
205.07 | 16.93B | 8.31B | 747.89M | 1.23B | 8.97 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | 개시 | Redburn Atlantic | Neutral |
| 2024-09-18 | 개시 | Leerink Partners | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2023-12-15 | 개시 | Truist | Buy |
| 2023-09-13 | 개시 | TD Cowen | Outperform |
| 2023-01-17 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-01-13 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-11-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-09-07 | 개시 | UBS | Buy |
| 2022-08-25 | 개시 | Credit Suisse | Neutral |
| 2022-05-24 | 개시 | Guggenheim | Buy |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2021-09-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-14 | 개시 | Citigroup | Neutral |
| 2021-04-13 | 재개 | BofA Securities | Neutral |
| 2021-04-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | 개시 | Barclays | Equal Weight |
| 2021-03-01 | 업그레이드 | UBS | Neutral → Buy |
| 2021-02-26 | 업그레이드 | Truist | Hold → Buy |
| 2020-07-24 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Hold |
| 2020-01-27 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-09-23 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | 업그레이드 | UBS | Sell → Neutral |
| 2019-01-25 | 업그레이드 | Mizuho | Neutral → Buy |
| 2018-10-26 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-10-09 | 개시 | UBS | Sell |
| 2018-04-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-15 | 재확인 | Mizuho | Neutral |
| 2018-01-19 | 개시 | Evercore ISI | Outperform |
| 2017-10-27 | 재확인 | Barclays | Equal Weight |
| 2017-09-11 | 개시 | BofA/Merrill | Buy |
| 2017-07-31 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-27 | 재확인 | Mizuho | Neutral |
| 2017-06-29 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Icon Plc 주식(ICLR)의 최신 뉴스
Icon (ICLR) 3-Year EPS without NRI Growth Rate : 8.70% (As of Sep. 2024) - GuruFocus.com
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates - MSN
Icon sees FY25 adjusted EPS $13.00-$15.00, consensus $14.93 - Yahoo Finance
Icon PLC (ICLR) Stock Price Down 6.6% on Jan 14 - GuruFocus.com
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty - Benzinga
ICON plc stock retains Overweight rating amid conservative growth forecasts - Investing.com India
ICON plc stock retains Overweight rating amid conservative growth forecasts By Investing.com - Investing.com South Africa
Clinical Trials Support Services Market Poised for Notable Expansion by 2030, Driven by Substantial Investments in R&D from Pharmaceutical and Biopharmaceutical Companies - GlobeNewswire Inc.
ICON Issues Financial Guidance for Full Year 2025 - sharewise
ICON plc Announces 2025 Financial Guidance Amid Market Challenges - TipRanks
Decentralized Clinical Trials Market Recent Growth: Market - openPR
ICON Public (NASDAQ:ICLR) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
ICON Survey: 97% Use Biomarkers in Neurodegenerative Trials, But Innovation Gaps Persist - StockTitan
RBC Capital Initiates Coverage of ICON Public Limited (ICLR) with Outperform Recommendation - MSN
ICON's SWOT analysis: CRO giant faces headwinds amid long-term growth potential - Investing.com India
ICON plc draws bullish views at RBC on attractive valuation - MSN
Icon PLC (ICLR) Stock Price Up 4.66% on Jan 7 - GuruFocus.com
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
ICON plc to Present at the J.P. Morgan Healthcare Conference - TipRanks
Why Icon Plc Shares Face Rocky Times Ahead - TipRanks
ICON Properties Plc (ICON.mw) Q42024 Interim Report - AfricanFinancials
ICON Clinches TIME Magazine's Top CRO Ranking, Dominates Industry Awards in 2024 - StockTitan
ICON appoints Barry Balfe as COO - MSN
Bioanalytical Services Market Key Players AnalysisPPD, Inc., - openPR
ICON plc appoints Barry Balfe as new COO By Investing.com - Investing.com Australia
ICON plc Appoints Barry Balfe as Chief Operating Officer - TipRanks
ICON plc appoints Barry Balfe as new COO - Investing.com
ICON Appoints 20-Year Veteran Barry Balfe as Chief Operating Officer to Drive Strategic Growth - StockTitan
Truist cuts ICON price target to reflect company commentary - Investing.com
ICON's SWOT analysis: CRO giant navigates turbulent market - Investing.com
October 2025 Options Now Available For Icon - Nasdaq
Contract Research Organization Services Market Set to Witness Significant Growth by 2024-2031: IQVIA, LabCorp, - EIN News
ICON's SWOT analysis: cro stock navigates challenges amid industry shifts - Investing.com
Preclinical Assets Market CAGR of 7.5% Size, Share, Trends, Future Prospect By 2024-2031 | Eurofins - EIN News
Biomarker Research Services Market Set to Witness Significant Growth by 2024-2031:Reprocell Corporation, - EIN News
At US$219, Is ICON Public Limited Company (NASDAQ:ICLR) Worth Looking At Closely? - Simply Wall St
ICON Public Limited Company (ICLR) Fell on Reduced Guidance - Insider Monkey
Virtual Clinical Trials Market Key Players AnalysisICON, plc; Parexel International Corporation; IQVIA; Covance. - openPR
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption - sharewise
Top 30 IQVIA Alternatives & Competitors in 2025 - Marketing91
Icon PLC (ICLR) Down 4.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
ICON (NASDAQ:ICLR) stock performs better than its underlying earnings growth over last five years - Simply Wall St
Should You Retain Your Conviction in Icon Plc (ICLR)? - Yahoo Finance
ICON stock labeled a "Fresh Pick" as Baird bets on recovery at current valuation - Investing.com
Pharmacovigilance and Drug Safety Software Market Skyrockets to $359.30 Million by 2031 Dominated by Tech GiantsArisEurope, ICON plc and Syneos Health | The Insight Partners - GlobeNewswire
Redburn Atlantic Initiates Coverage of ICON Public Limited (ICLR) with Neutral Recommendation - MSN
ICON Public Limited (NASDAQ:ICLR) Shares Sold by Entropy Technologies LP - MarketBeat
ICON Public Limited Company (ICLR): Among 12 High Growth Large Cap Stocks to Buy Now - Yahoo Finance
Icon Plc (ICLR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.28%
자본화:
|
볼륨(24시간):